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Abstract 18 
The increasing prevalence of wound infections caused by antibiotic resistant bacteria is an urgent 19 
challenge facing modern medicine. To address this issue the expedient use of antimicrobial metals 20 
such as zinc, copper and silver were incorporated into an FDA-approved polymer (polycaprolactone - 21 
PCL) to produce filaments for 3D printing. These metals have broad-spectrum antimicrobial 22 
properties, and moreover, copper and zinc can enhance the wound healing process. 3D scanning 23 
was used to construct 3D models of a nose and ear to provide the opportunity to customize shape 24 
and size of a wound dressing to an individual patient. Hot melt extrusion was used to extrude pellets 25 
obtained by vacuum-drying of solutions of PCL and the different metals in order to manufacture 26 
metal-homogeneously-loaded filaments. Wound dressings with different shapes were produced with 27 
the filaments containing different concentrations of metals. Release of the metals from the dressings 28 
was determined by inductively coupled plasma atomic emission spectroscopy. All the different metal 29 
dressings show fast release (up to 24 h) followed by slow release (up to 72 h). The antibacterial 30 
efficacy of the wound dressings was tested using a thermal activity monitor system, revealing that 31 
silver and copper wound dressings had the most potent bactericidal properties. This study shows 32 
that 3D scanning and 3D printing, which are becoming simpler and more affordable, have the 33 
potential to offer solutions to produce personalised wound dressings.  34 
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1 Introduction  47 
The skin is the largest organ in the body, functioning as a sensory system, regulating both 48 
temperature and moisture transmission and acts as a physical barrier against the external 49 
environment. When a wound occurs, due to trauma or disease, the barrier becomes compromised. 50 
This can increase the susceptibility of the wound site to microbial infections originating from 51 
endogenous sources, such as surrounding skin and mucous membranes, or from exogenous sources, 52 
such as those introduced by injury or from the local environment (Landis, 2008). The introduced 53 
microorganism may overcome the host’s defences and invade into deeper tissues, progressing to a 54 
more severe infection, thus causing further damage and delaying healing of the wound (Siddiqui and 55 
Bernstein, 2010). 56 
A wound may require the application of an external dressing to temporarily compensate for the 57 
damaged barrier and to allow healing to initiate and progress. A wound dressing isolates the injury 58 
site from the external environment, and provides an optimal environment for the wound to heal by 59 
promoting haemostasis and limiting tissue oedema through external compression (Zahedi et al., 60 
2010). Wound dressings, traditionally used to protect the wound from contamination, can be used 61 
as platforms to deliver actives to wound sites. The use of solid wound dressings is preferred to the 62 
use of topical bioactive agents in the form of solutions, creams, and ointments in the case of 63 
exudative wounds for drug delivery to the wound as they provide better exudate management and 64 
prolonged residence at the wound site. These dressings are potentially useful in the treatment of 65 
local infections being beneficial to achieve increased local concentrations of antibiotics while 66 
avoiding systemic treatment, thus reducing patient exposure to an excess of drug beyond that 67 
required at the wound site (Boateng and Catanzano, 2015). 68 
Due to the alarming increase of multi-drug resistance bacteria worldwide, caused by the over-use 69 
and miss-use of antibiotics, the application of broad-spectrum antimicrobial agents such as metal 70 
ions is an attractive target. Having been used historically for their antimicrobial properties(Lemire et 71 
al., 2013; Tenaud et al., 2009), the use of inorganic antimicrobial metals in the fight against 72 
infections is of high importance due to the fact that they act on multiple bacterial pathways, which 73 
makes it difficult for the bacteria to develop resistance against them (Huh and Kwon, 2011). Silver is 74 
probably the most commonly used metal, but zinc and copper, two of the essential trace elements in 75 
the human body, are also known to play an integral part in the wound healing process.  76 
Silver ions have been shown to bind to various bacterial cell membrane proteins to cause cell lysis, 77 
and can be transported into bacterial cells, where silver ions disrupt the cell wall to interfere with 78 
energy production, enzyme function, cell replication and ultimately cell death (Chopra, 2007; Fong 79 
and Wood, 2006; Jain et al., 2009). There remains a concern in relation to the toxicity of silver to 80 
humans, however, most frequent side effects including local skin irritation, discolouration or staining 81 
which are harmless and usually reversible (Cutting et al., 2007). Copper ions function by altering 82 
proteins and inhibiting their biological activity, membrane lipid peroxidation, and plasma membrane 83 
permeabilization (Borkow and Gabbay, 2005; Gabbay et al., 2006). Copper can improve the healing 84 
process as it plays a key role in the enhancement of angiogenesis, via induction of vascular 85 
endothelial growth factor (VEGF), up-regulating the activity of copper-dependent enzymes, cell 86 
proliferation and re-epithelisation (Liu et al., 2009). It is suggested that the mode of action of ZnO is 87 
due to the disruption of bacterial cell membranes, and zinc is involved in several transcription 88 
factors and enzyme systems, stimulates the proliferation of epidermal cells, and increases collagen 89 
synthesis. Topical zinc can improve the healing of wounds especially in patients with zinc deficiency 90 
(Lemire et al., 2013), which can be a result of hereditary causes (Lansdown et al., 2007). 91 
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Wound dressings are usually prepared from absorbent, cross-linked polymer networks. One 92 
potential polymer is polycaprolactone (PCL), a semi-crystalline polyester that is biodegradable and 93 
biocompatible. These properties have led to the approval of several PCL drug-delivery devices and 94 
implants by the FDA (Salgado et al., 2012). It has a slow rate of degradation in-vivo compared with 95 
other biodegradable polyesters, a property that can be exploited in the manufacture of controlled 96 
release formulations (Li et al., 2014). PCL has been widely investigated in wound and burn dressings 97 
(Boateng et al., 2008; Ng et al., 2007), tissue engineering (Kweon et al., 2003), scaffold 98 
manufacturing (Kamath et al., 2014) and drug targeting (Freiberg and Zhu, 2004). 99 
Three-dimensional printing (3DP) is a recently developed technology with numerous possibilities for 100 
the manufacture of medical devices. 3DP is an additive manufacturing process that allows the 101 
fabrication of three dimensional solid objects of virtually any shape. Of the several types of 3D 102 
printing, fused deposition modelling (FDM) has been most widely used for medical devices as it is 103 
simple, cost effective and extrudes polymer strands (Goyanes et al., 2016a; Yu et al., 2008). The 104 
printer feedstock is a thermoplastic filament that is heated to its softening point and then extruded 105 
through a print-head (driven by an X – Y orientation system) layer by layer over a build plate. The 106 
build plate is then lowered to a predetermined height and the process is repeated until the 3D 107 
object has been constructed. FDM 3DP has been used in various fields, such as tissue engineering, 108 
scaffold manufacturing (Fielding et al., 2012), and to produce oral drug delivery formulations 109 
(Goyanes et al., 2014; Goyanes et al., 2015a; Goyanes et al., 2016b; Goyanes et al., 2015b; Melocchi 110 
et al., 2015; Pietrzak et al., 2015). The ‘instructions’ for the 3D printer on how to build the object 111 
comes from the printer’s software that slices the source digital file into layers that form the 112 
instructions for the 3D printer. This digital file can be created using computer-aided design software, 113 
to construct a new 3D object, or with the use of 3D scanning, to copy an existing object. 3D scanning 114 
is a non-contact, non-destructive technology that digitally captures the shape of physical objects 115 
with a 3D scanner using laser light that collects distance information from surfaces. This information 116 
is then used to create ‘point clouds’ of data from the surface of the object. Hence, 3D laser scanning 117 
is a way to capture a physical object’s exact size and shape to construct a 3D model (Koch, 2012). 118 
The proof of concept of combining 3D printing and 3D scanning for the manufacture of antiacne 119 
masks/patches has been previously reported (Goyanes et al., 2016a), whereas the use of FDM 120 
printing showed high drug degradation due to the heating process while printing. 121 
The combination of 3D printing and 3D scanning could possibly revolutionise patient care by 122 
allowing custom-manufacture of devices for individual patients and it is the exploration of this 123 
concept, applied specifically to wound dressings, that is the focus of this work. Hot melt extrusion 124 
was used to incorporate metal ions into a PCL filament and the 3D printer was used to fabricate 125 
dressings against scanned templates of a target wound. The antimicrobial efficacy of the dressings 126 
was also assessed using an in-vitro assay.  127 
 128 
2 Materials and Methods 129 
2.1 Materials 130 
PCL pellets ((C6H10O2)n, Mw ∼ 80,000) and silver nitrate (AgNO3) were purchased from Sigma-131 
Aldrich, UK. Copper sulphate (II) pentahydrate (CuSO4·5H2O) was purchased from VWR chemicals, 132 
Belgium. Zinc oxide (ZnO) was purchased from Alfa Aesar, USA. The test organism Staphylococcus 133 
aureus (NCIMB 9518) was purchased from Fisher Scientific, UK. Nutrient broth (CM0001) was 134 
purchased from Thermo Scientific, UK.  135 
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 136 
2.2 Methods 137 
2.2.1 Preparation of metal loaded filaments 138 
- Silver-loaded filament (10% loading w/w):  139 
AgNO3 (3 g) was dissolved in 10 mL of deionized water using a magnetic stirrer. Tetrahydrofuran 140 
(THF, 200 mL) was added to the silver solution under stirring. Finally, 27g of PCL pellets was then 141 
added to the solution and the mixture was stirred at 40 °C until complete dissolution of PCL. The 142 
solvents were removed with a rotary evaporator under reduced pressure at 40 °C for 2 h followed by 143 
high-vacuum drying for 1h. The dried material (AgNO3 homogeneously distributed in the PCL) was 144 
chopped into pellets and extruded with Filabot filament hot-melt extruder (Filabot Inc, USA) with a 145 
single screw and a 1.75 mm nozzle head. The extrusion temperature was 80 °C.  146 
 147 
- Copper-loaded filament (10 and 25% loading w/w):  148 
CuSO4·5H2O (3g or 7.5g for 10% or 25% loading respectively) was dissolved in 100mL methanol using 149 
a magnetic stirrer. PCL pellets (27 g or 22.5 g for 10% or 25% copper loading respectively) was then 150 
added to the copper solution, followed by 100mL dichloromethane (DCM) and the mixture was 151 
stirred at 40°C until complete dissolution of PCL. A rotary evaporator (under reduced pressure) was 152 
used to evaporate the solvents at 40 °C for 3 h followed by high-vacuum drying for 1 h. The dried 153 
material (CuSO4 homogeneously distributed in the PCL) was chopped into pellets and extruded with 154 
Filabot filament hot-melt extruder (Filabot Inc, USA) with a single screw and a 1.75mm nozzle head. 155 
The extrusion temperature was 60°C.  156 
 157 
- Zinc-loaded filament (10 and 25% loading w/w):  158 
ZnO (3g or 7.5g for 10% or 25% zinc loading respectively) was dissolved in 100 mL ethanol using a 159 
magnetic stirrer. PCL pellets (27g or 22.5g for 10% or 25% copper loading respectively) was added 160 
followed by 100 mL DCM and the mixture was stirred at 40°C until complete dissolution of PCL. The 161 
solvents were removed using a rotary evaporator at 40 °C for 3 h followed by one hour high-vacuum 162 
drying. The dried material (ZnO homogeneously distributed in the PCL) was chopped into pellets and 163 
extruded with Filabot filament hot-melt extruder (Filabot Inc, USA) with a single screw and a 164 
1.75mm nozzle head. The extrusion temperature was 75°C.  165 
 166 
For all the filaments prepared the diameter of the filament was checked using a digital calliper 167 
throughout the extrusion process, since it is important to get a consistent filament diameter within 168 
an acceptable range for the 3D printer. 169 
 170 
2.2.2 3D Scanning  171 
3D scans were captured with a Sense 3D Scanner (3D Systems, USA). It functions by capture of the 172 
surface data of a physical object reflected light from a laser. In this work, scans were captured of a 173 
nose and ear, because 3D printed dressings of these body parts can dress anatomically complex 174 
areas compared to conventional flat dressing, what would provide more comfort to the patient. The 175 
settings used were high resolution, with object recognition enabled, colour scanning and landscape 176 
orientation. The person being scanned was in a setting position, while the person holding the 3D 177 
scanner was rotating 360°around the subject while maintaining about 40 cm distance to the 178 
subbject. These 3D scans were cut, optimized for 3D printing and templates were made using 179 
Autodesk Meshmixer 10.8.  180 
2.2.3 3D Printing 181 
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A MakerBot Replicator 2X Desktop 3D printer (MakerBot Inc., USA) was used to print wound 182 
dressings shaped to match the nose and ear scans, in addition to square dressings (20 x 20 x 1 mm) 183 
for antimicrobial studies and circular dressings (10 mm diameter x 1 mm thickness) for dissolution 184 
testing. The templates for the square and circular dressings were created using Tinkercad (Autodesk) 185 
– a browser-based 3D design and modelling tool. 186 
 187 
The nozzle head was cleaned (for 20 – 25 s) prior to printing the metal-loaded filaments, and 188 
between prints containing different metal ions or different concentrations, by extruding plain PCL 189 
filament. The settings of the printer, which will ultimately determine how the 3DP dressings will turn 190 
out, were selected based on preliminary results with the metal loaded filaments. All the dressings 191 
were printed at an extrusion temperature of 170 °C, high resolution (0.1 mm layer height), with two 192 
shells, 100% infill and speed while extruding and while travelling was set to 50 mm/s. A raft and 193 
support were used for the printing of the nose and ear dressings, while no support or raft was used 194 
for the printing of the flat dressings printed for analytical purposes.   195 
 196 
2.2.4 Thermal characterisation of metal-loaded filaments and  dressings 197 
Differential scanning calorimetry (DSC): Measurements of the metal loaded filaments and the 3D 198 
printed dressings were performed using a TA Q2000 DSC (TA Instruments LLC, USA), calibrated with 199 
indium (Tm = 156.6 °C, ΔHf = 28.71 J/g). Nitrogen gas was used as a purge with a flow rate of 50 200 
mL/min. Tzero hermetic pans with lids were used for all samples, with an average sample weight of 201 
7-9 mg. Samples were cooled to -80 °C then heated to 200 °C at a heating rate of 10 °C/min. 202 
 203 
Thermogravimetric analysis (TGA): TGA analysis was performed with TA Discovery TGA (TA 204 
Instruments LLC, USA) with nitrogen as purge (flow rate = 25 mL/min). Open aluminium pans were 205 
used, and samples were heated from room temperature (15 ± 0.5 °C) to 200 °C at 10 °C/min.   206 
 207 
2.2.5 Scanning electron microscopy (SEM) 208 
Surface and cross-section images of the filaments were taken using JSM-840A Scanning Microscope, 209 
JEOL GmbH, Germany. The voltage and working distance were set at 5 kV and 50 mm, respectively. 210 
Filament samples were placed on double-sided carbon tape, mounted on stubs and sputter coated 211 
using a Polaron E5000 machine with Au/Pd. Samples were coated for 1 minute prior to imaging.  212 
 213 
 214 
 215 
2.2.6 Fourier transform infrared (FTIR) spectroscopy 216 
FTIR spectra of Ag, Cu and Zn powder, filaments and dressings were acquired using Bruker ALPHA 217 
Platinum FT-IR spectrometer (USA) to determine if Ag, Cu or Zn form any bonding with the 218 
polycaprolactone matrix. Spectra were acquired at 4000 cm-1 to 400 cm-1 and a resolution of 2 cm-1.  219 
 220 
2.2.7 Dissolution testing of wound dressings 221 
For each assay the dressing was placed into a sterile 10 mL vial with agitation in the dissolution 222 
medium (10 mL of 0.1 M phosphate buffer – pH 7.4). The vials were capped and incubated in a 223 
thermostated bath at 37 °C for three days. At regular intervals (0, 6, 12, 18, 24, 36, 48, 60 and 72 h), 224 
1 mL aliquots were sampled from each vial and replaced with an equal amount of phosphate buffer. 225 
The samples were then diluted to 5 mL with 96% (w/w) nitric acid (to digest any dissolved polymer 226 
matrix), stirred at room temperature for 1 h, then 1 mL was taken from that solution and diluted 227 
further to 20 mL with phosphate buffer.  228 
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Analysis of the samples was performed with Inductively Coupled Plasma Atomic Emission 229 
Spectroscopy (ICP-AES) using an Axial Varian 720-ES, with argon as a purge gas. Ag was analysed at 230 
wavelength 328.068 nm, Cu at 327.395 nm and Zn at 213.857 nm. A second wavelength (338.289 nm 231 
for Ag, 324.754 nm for Cu and 202.548 nm for Zn) was used to confirm the reproducibility of the 232 
results. Each dressing was tested in triplicate and the mean value determined.  233 
 234 
2.2.8 Antibacterial efficacy of wound dressings  235 
Antibacterial efficacy of wound dressings was tested against S. aureus which is a common bacterium 236 
to causes skin infections. S. aureus, stored in 1 mL aliquots at -80 °C in 15% w/v glycerol, was 237 
defrosted at 37 °C and used to inoculate nutrient broth, which was incubated overnight aerobically 238 
at 37 °C. Bacteria were harvested from the broth by centrifugation at 3000 g for 10 min and washed 239 
in phosphate buffered saline (PBS) (Fisher Scientific, UK) three times.  The resulting bacterial 240 
suspension was adjusted to a 0.5 McFarland standard using PBS to standardize the cell numbers to 241 
approximately 1 x 108 cfu/mL.  This was verified with serial dilution and spread plating.      242 
 243 
Dressing samples (plain PCL, Ag-PCL, Cu-PCL, and Zn-PCL) printed with identical settings (see 3D 244 
printing above) were cut to the required weights (10, 20, 25, 30, 40, 50, 75 and 100 mg) immediately 245 
prior to use and inserted into a sterile 3 ml calorimetric ampoule (Hichrom, UK).  Nutrient broth 246 
(2.97 mL) was added to the ampoule, followed by inoculation with the bacterial suspension (30 µL). 247 
The ampoule was then sealed with a crimp cap.  A control ampoule was prepared for each 248 
experiment containing only nutrient broth and the same inoculum of bacteria. The ampoule was 249 
vortexed briefly before being transferred to a 2277 Thermal Activity Monitor (TAM, TA Instruments 250 
Ltd, UK). 251 
 252 
The ampoules were allowed to equilibrate for up to 30 min before being lowered into the measuring 253 
position of the TAM (set at 37 °C with an amplifier setting of 1000 µW). Digitam 4.1 software 254 
collected heat output data every 10 s for 48 h. 255 
 256 
After calorimetric analysis, ampoules were removed from the TAM and inspected for turbidity. Non-257 
turbid ampoules were vortexed for 10 s then opened and 1 mL of nutrient broth removed to 258 
enumerate the bacteria.  The sample was centrifuged at 3000 g for 10 min and resuspended in PBS 259 
three times in an attempt to remove any metal ions that could affect the growth of the bacteria on 260 
agar. The resulting bacterial suspension underwent serial dilution and spread plating on ISA, 261 
followed by incubation overnight at 37 °C. Colonies were counted, and the number of viable bacteria 262 
in the ampoule calculated.   263 
 264 
3 Results and Discussion 265 
The manufacture of metal-loaded filaments for 3D printing was achieved with PCL. Five metal loaded 266 
PCL filaments were produced with different concentrations: Ag (10% w/w)-PCL, Zn (10% w/w)-PCL, 267 
Zn (25% w/w)-PCL, Cu (10% w/w)-PCL and Cu (25% w/w)-PCL (Figure 1). The average filament 268 
diameter was 1.77 ± 0.3mm. The metal compounds and the PCL were dissolved in an appropriate 269 
solvent mixture and the solution vacuum-dried to obtain pellets with a homogeneously distribution 270 
of the metal compound into the PCL. 271 
 272 
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One of the most challenging parts of the process was the determination of a common solvent to 273 
dissolve both the metal and polymer. For instance, CuSO4·5H2O and AgNO3 were soluble in water 274 
while ZnO and PCL were insoluble in water. It was established that a single solvent was not adequate 275 
to dissolve both the polymer and any of the metals so ultimately a combination of solvents was used 276 
to dissolve PCL and the metals (see Methods for the exact combination for each preparation). This 277 
method is cheap, versatile and only requires the selection of suitable solvents, moreover the direct 278 
extrusion of the metal compounds and PCL is not recommended since that lead to filaments with a 279 
very poor distribution of the metal compounds in the PCL. 280 
Two factors were critical in ensuring extrusion produced a filament of consistent diameter. Firstly, 281 
the extrusion temperature varied depending on the mixture content and how dry the mixture was. 282 
Copper-containing mixtures required a lower extrusion temperature (60 °C) compared with the non-283 
copper-containing mixtures (which were extruded at 75 – 80 °C). This could be due to the lower 284 
melting temperature of CuSO4·5H2O (110 °C) compared with AgNO3 (212 °C) and ZnO (1975 °C).  285 
When the extrusion temperature was lower than required, it led to a thicker filament and/or 286 
clogging of the extruder. Higher extrusion temperatures led to the extrusion of filaments that were 287 
thin and inconsistent (about 1.35 ± 0.05 mm). Secondly, a regular feeding rate was required to 288 
produce a uniform filament diameter.  289 
SEM micrographs of the filaments revealed that all the filaments had homogenous and uniform 290 
surface and cross section, indicating uniform metal distribution inside the filaments (Figure 2).  291 
3D templates for wound dressings were successfully obtained from 3D scanning. The resolution of 292 
the 3D scanner was one of the main factors determining the quality of the 3D scans, however, 293 
lighting conditions (e.g. direct sunlight) and room temperature did affect the depth of acquisition of 294 
the scanner. 295 
Ag, Cu and Zn loaded PCL dressings were printed. Figure 3 shows an example of a Cu-PCL printed 296 
nose dressing (see Appendix 1 for more examples). All the dressings were flexible, most likely due to 297 
the elastomeric properties of PCL. These 3D printed dressings have an advantage over conventional 298 
flat dressing in that they can dress anatomically complex areas. This would provide more comfort to 299 
the patient and improve adherence. The cytocompatibility of PCL in addition to the possibility of 300 
incorporating bioactive or antimicrobial agents means that PCL has the potential to be tailored into 301 
an effective wound dressing with appropriate bio-physical properties (e.g. vapour permeability and 302 
flexibility) and personalised shape and size. The use of metal ions improves the printing performance 303 
of the PCL filaments. In a previous study using PCL filaments loaded with salicylic acid for the 304 
treatment of acne, the 3D printer was able to manufacture flat disc/patches but not complex shapes 305 
as personal shape devices (Goyanes et al., 2016a). 306 
FTIR spectra of plain PCL pellets (before 3D printing) exhibited both absorption bands of the –C–H 307 
and C=O functional groups at 2942 cm-1 and 1722 cm-1 respectively (Figure 4). FTIR analysis of the 308 
printed plain PCL, Ag(10%)-PCL, Cu(10%)-PCL, Cu(25%)-PCL, Zn(10%)-PCL and Zn (10%)-PCL showed 309 
all absorption bands of the functional groups (–C–H and C=O). In addition, there was no shift in peak 310 
positions of the metal-loaded 3D printed samples compared to plain PCL pellets or 3D printed PCL, 311 
indicating that there was no chemical bonding between PCL, Ag, Cu or Zn had occurred during 312 
extrusion and printing of the dressings.  313 
The main limiting factor in printing good dressings was a consistent filament diameter within an 314 
acceptable range for the 3D printer. A filament thin in sections resulted in areas of the dressings 315 
containing less material than other areas, and thicker filament sections were too difficult for the 316 
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extruder head to grip. Thus, after various experimentations with slight variations in filament 317 
diameters, it was determined that the consistency of the filament diameter (1.69 – 1.77 mm) was 318 
more important than the size of the diameter (given that it is within acceptable range of the 3D 319 
printer; 1.60 – 1.79 mm).   320 
3D printing of wound dressings of good quality requires an understanding of the settings that will 321 
ultimately dictate how they would turn out. For dressings printed in this work, these settings were 322 
the layer height, number of outer shells and both speed while extruding and travelling.  These 323 
settings, individually or combined, did directly control the surface finish, density and quality of the 324 
final print.  325 
Increasing the number of shells (the outer most layers of the print) provided stronger dressings; 326 
however, they increased printing time and reduced quality (e.g. 4 shells resulted in substantial 327 
reduction of details and inconsistent surface of printed dressings compared to 2 shells). Having too 328 
few shells resulted in a weak and fragile print. There needs to be a balance between not having 329 
enough or too many shells, and in this case, the default of two outer shells was a good compromise.  330 
The resolution of the 3D printed dressing is determined by the layer height. Using a smaller layer 331 
height provided a considerable increase in detail and increased printing time. The MakerBot 332 
Replicator 2X can print in layer heights between 0.1 mm and 0.3 mm, however it was only possible 333 
to obtain good quality prints with 0.1 mm layer heights. One reason for this is because 3D prints 334 
made with FDM printers typically have visible ridges between different layers, and a smaller layer 335 
height helps to reduce (but not eliminate) them.  336 
The printing temperature in addition to both printing and movement speed determine if it is 337 
possible to print at all. The extrusion temperature depends on the filament material being used, for 338 
instance, plain PCL dressings could be printed with as low as 140 °C. However, when PCL is loaded 339 
with metals, it was not possible to print until this temperature was increased to 170 °C. High 340 
movement speed while printing or travelling reduced the printing time by making the print-head 341 
move faster, but resulted in poorer print quality. On the other hand, slower speed meant that the 342 
hot print-head would stay longer above the extruded layers resulting in burnt layers, especially the 343 
last layers. The optimal settings found in this case was 50 mm/s for both printing and travelling 344 
speeds. 345 
 346 
The DSC thermogram (Figure 5) shows that plain PCL dressing has a melting temperature (Tm) of 347 
60.9°C and a glass transition temperature (Tg) of -63.4 °C which agrees with the literature values of 348 
PCL pellets (60.0 °C and -60.0 °C respectively) (Hutmacher et al., 2001). All the metal loaded 349 
dressings show similar thermal profiles compared with the plain PCL dressing without any 350 
degradation at temperatures up to 200 °C. Ag-PCL had the lowest Tm (59.4 °C) while Zn-PCL had the 351 
highest (61.8 °C). Ag-PCL dressing decreased the Tm while both Zn-PCL and Cu-PCL dressings 352 
increased it slightly, these changes did not have effect on the printability of the filaments.  353 
TGA showed no significant mass loss (0.44% to 1.89%), most likely due to loss of residual solvents. 354 
Copper-containing dressings (10 and 25% w/w) showed the highest amount of weight loss (1.63% 355 
and 1.89% respectively) compared with the other dressings. This could be due to the hygroscopicity 356 
of copper sulphate. This might become an issue in the future during storage and transport of the 357 
dressings. However, with proper storage conditions and packing this concern can be overcome.  358 
Thus it can be concluded that the thermal analysis results confirm that the printed dressings were 359 
stable and that the printing and extrusion processes did not affect the properties of PCL. It is 360 
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important to note that even though the residence time of the formulation in the print head is short 361 
(a few seconds), thermally labile formulations may experience some degree of degradation during 362 
the printing process (Goyanes et al., 2016a). Hence, DSC analysis may be used to assess the 363 
suitability of the formulation for FDM 3D printing (Goyanes et al., 2015a). 364 
One of the challenges in antimicrobial research for wound dressings is achieving sustained release of 365 
the antimicrobial agent for extended prevention of bacterial infection. The release of Ag, Cu and Zn 366 
from PCL dressings to the surrounding environment is shown in Figure 6. During the first 24 h of the 367 
experiment, Ag was released very quickly (40.69 µg/mL), but the release rate decreased rapidly in 368 
the following 24 h reaching a concentration of 44.53 µg/mL at 48h. From 48 to 72 h the 369 
concentration of Ag remained almost constant at 45.85 ± 1.10 µg/mL. The fast release observed in 370 
the first 24 h is most likely the release of Ag from the surface of the PCL matrix, and the slower 371 
release afterwards is due to the slow diffusion of Ag from the interior of the polymer matrix to the 372 
surface before release. The final concentration (44.53 µg/mL) is two folds higher than the minimum 373 
inhibitory concentration and minimum bactericidal concentration previously reported for silver 374 
against S. aureus (22.083 µg/mL) (Said et al. 2014). 375 
 376 
Over the same time period (0 – 72 h) the concentration of Cu and Zn had the same trend but was 377 
always much lower compared to Ag. The release rate was highest for 10% Ag-PCL (45.85 µg/mL) and 378 
lowest for 10% Zn-PCL (15.87 µg/mL). Both 25% Cu-PCL and 25% Zn-PCL had higher release rate 379 
compared to their corresponding 10% dressings. This is due to the fact that the metal content in the 380 
25% dressing is higher than the 10% leading to more metal being released. 25% Cu-PCL had higher 381 
release rate than 25% Zn-PCL (same applies for the 10% dressings of both metals). Minimum 382 
inhibitory concentration for copper against S. aureus was reported to be between -3 – 40 µg/ml, 383 
being the minimum bactericidal concentration between 7 and 60 µg/ml (Argueta-Figueroa et al. 384 
2014). The amount of copper released from the dressings was 17.756 µg/ml (for 10%) and 26.634 385 
(for 25%), values which fall in the middle of the reported values. However, the antibacterial efficacy 386 
of Zn and Cu is dependent on the concentration of the metal, the initial bacterial concentration, and 387 
the strains of bacteria employed in the study.  388 
The minimum inhibitory concentrations found in the literature for Zn against S. aureus are very 389 
variable and not comparable to the test performed in this study. Zn nanoparticles vs S. aureus 390 
showed a minimum inhibitory concentration determined by agar dilution method of 625 µg/ml 391 
(Aleaghil et al. 2016). The highest concentrations obtained were 15.87 µg/ml for 10% and 20.63 392 
µg/ml for 25% Zn wound dressings, which are significantly lower than the concentration reported.  393 
 394 
The controlled release of Ag, Cu and Zn from PCL dressings is attributed to the entrapment of the 395 
metals into PCL, which acts as a barrier for the release of these metals from the dressing due to the 396 
slow water penetration into the PCL matrix. These results confirm that entrapment of metal ions 397 
into PCL dressings delays the release of the metals. This is desirable to maintain sufficient release of 398 
antimicrobial agent to remain active for the duration of treatment, while preventing high 399 
concentrations to be released upon initial application which would prevent adverse events (such as 400 
irritation) from high doses. Another advantage of a slower and prolonged release rate of Ag, Zn and 401 
Cu in clinical practice is that it would reduce the number of dressing changes, which can be very 402 
painful (Meaume et al., 2004). 403 
 404 
These results are in agreement with the solubility of the metals in water (majority constituent of the 405 
phosphate buffer testing medium) where Ag has superior solubility properties, followed by Cu then 406 
Zn. Ideally, the dissolution testing could have been performed in the same medium used in the 407 
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antibacterial testing. This could give a better correlation between release profiles of the metals from 408 
dressings and antibacterial activity. However, that was not possible as the nutrient broth used for 409 
antibacterial testing contains NaCl which led to the precipitation of solid AgCl when Ag-PCL dressing 410 
was dissolved in the medium during the initial experiments. Moreover, pH 7.4 of the phosphate 411 
buffer resembles the pH at surface of the skin providing closer correlation to the in-vivo 412 
environment.  413 
Isothermal micro-calorimetry (IMC) was used to quantitatively monitor the efficacy of silver, zinc and 414 
copper in wound dressings. IMC monitors the rate of heat production (power) in a sample, where 415 
the power signal is proportional to the number of viable cells in the sample. This allows for real-time 416 
measurement of the growth (or inhibition) of S. aureus, without being affected by non-viable cells. 417 
This method is not dependent on optical clarity (which can be effected by the presence of the metal 418 
ions in the sample), and does not require the organism to be removed from its environment to be 419 
sampled (Gaisford et al., 2009; O’Neill et al., 2003). The drawback of IMC is that because heat is 420 
absorbed or produced by different events occurring in the sample, could mean that the power signal 421 
measured is potentially a combination of several processes. However, a careful experimental design 422 
can improve these issues as discussed by S. Gaisford et al. (Gaisford, 2005). 423 
The control experiments of S. aureus (without any dressing or metals) shows a characteristically 424 
complex pattern, exhibiting an exponential growth phase in the first few hours with two distinctive 425 
biphasic peaks, during which heat is generated and an increase in power is recorded (Figure 7A). The 426 
area under the curve (AUC – total heat output) of the controls is reproducible (n = 3) to 3.5%. As 427 
discussed by Zaharia et al. (2013), the first exponential phase (0 – 3 h) represents aerobic 428 
metabolism where the available oxygen (blue arrow in Figure 7A), dissolved in the medium is utilised 429 
(the ampoules are sealed but not completely filled to the top). This is then followed by a change in 430 
aerobic metabolism (3 – 10 h) using diffused oxygen from the head space of the ampoule (red arrow 431 
in Figure 7A). The last peak of the thermogram represents anaerobic metabolism of the organism 432 
using any remaining carbon sources that the organism is able to metabolise (green arrow in Figure 433 
7A) (Zaharia et al., 2013). The exhaustion of nutrients, pH drift and the appearance of toxic 434 
metabolites consequently stopping the organism from growing anymore. This resulted in the power 435 
signal to return to baseline (zero) and hence decided the 48 hour duration of the experiment.  436 
 437 
In the presence of plain 3D PCL dressings (i.e. the dressings with no antimicrobial metal agent), PCL 438 
showed no effect on the initial aerobic phase and the overall growth is very similar to that of the 439 
control (Figure 7B). There was very slight variation in the second growth phase which was attributed 440 
to microorganism cells becoming entrapped within the PCL dressing. Therefore, diffusion of medium 441 
to those trapped cells and metabolites from those microorganisms to the medium will be different 442 
compared to those present in the surrounding medium only. Thus, it can be concluded that PCL does 443 
not have any intrinsic antimicrobial properties, and increasing amounts of PCL does not affect the 444 
growth of S. aureus.    445 
 446 
The shape of the growth curve is significantly different in the presence of 10% (w/w) Ag-PCL dressing 447 
(Figure 7C). Use of 10 mg of Ag-PCL dressing delayed the growth by ca. 16 h, and inhibition of growth 448 
was observed when larger masses (20, 30 and 40 mg) were used when compared to the control. 449 
Viable counts at the end of each experiment (Table 1) confirmed a bactericidal effect on the 450 
bacteria, with a three log reduction in bacteria compared to the inoculum. These results indicate 451 
that silver dressing is effective at inhibiting the growth of S. aureus via a bactericidal mechanism, and 452 
that increasing amount of silver causes a more potent inhibition.  453 
 454 
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Table 1. Viable cell counts after the IMC study 
Formulation 10% Ag - PCL 
Mass of the dressing Control (0g) 10 mg 20 mg 30 mg 40 mg 
Viable cells 140,333 105 20 0 0 
      
Formulation 10% Cu - PCL 
Mass of the dressing Control (0g) 25 mg 50 mg 75 mg 100 mg 
Viable cells 121,667 120,311 95,038 56,664 51,682 
      
Formulation 25% Cu - PCL 
Mass of the dressing Control (0g) 25 mg 50 mg 75 mg 100 mg 
Viable cells 120,660 14,738 1,202 220 48 
      
Formulation 10% Zn - PCL 
Mass of the dressing Control (0g) 25 mg 50 mg 75 mg 100 mg 
Viable cells 119,333 117,855 117,439 111,538 89,795 
      
Formulation 25% Zn - PCL 
Mass of the dressing Control (0g) 10 mg 20 mg 30 mg 40 mg 
Viable cells 119,916 84,764 81,297 71,859 68,315 
 467 
 468 
Figure 7D shows the corresponding growth curves for S. aureus in the presence of increasing masses 469 
of 10% (w/w) Cu-PCL. All the samples (10 – 40 mg) showed no inhibition of the microorganism. This 470 
indicates that at this concentration Cu is ineffective at inhibiting the growth of S. aureus after 48 h, 471 
due to a slow release rate or the concentration of Cu is not sufficient. Hence, 25% (w/w) Cu-PCL was 472 
tested to determine if there is any improvement with higher concentrations of Cu (Figure 7E). 473 
Several differences from the control are apparent, but the interpretation of these data is difficult. 474 
There is an absence of any of the characteristic growth peaks of S. aureus, with high-power peaks at 475 
the beginning with an immediate sharp decline in power instead. There was no growth in any of the 476 
samples, which was confirmed by the non-turbidity of all the samples after the TAM experiments. In 477 
addition, viable counts revealed that a 25 mg dressing showed a two log reduction in viable bacteria 478 
(while higher masses of the dressing had stronger inhibition) at the end of the TAM experiment 479 
compared to the initial inoculum (Table 1). This suggests that Cu is effective at inhibiting the growth 480 
of S. aureus, although higher concentrations are required compared to silver. In efforts to explain 481 
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the unusually high peaks at the start of the growth curves are due to Cu, the bacteria or an 482 
interaction between any of dressings’ content’s and that of the medium, copper sulphate powder 483 
only (without any bacteria or PCL) was tested exactly as the Cu-PCL dressing in water and broth. As 484 
can be seen in Figure 7F, both curves show a similar pattern to that of the 25% (w/w) Cu-PCL. This 485 
confirms that these peaks are due to copper sulphate powder and are not due to any interaction 486 
between the dressing content, bacteria or the medium.  487 
 488 
Both 25 and 50 mg of 10% (w/w) Zn-PCL dressing showed no effect on the growth of S. aureus after 489 
72 h (Figure 7G).  While 75 mg and 100 mg of the dressing showed a small reduction in the intensity 490 
of the growth peaks, and a minor delay of the growth. These results suggest that at these 491 
concentrations Zn is ineffective at inhibiting the growth of S. aureus, as confirmed by cell counting 492 
(Table 1). 493 
The results with 25% (w/w) Zn-PCL show stronger inhibition compared to the 10% (w/w) Zn-PCL 494 
dressing (Figure 7H). Both 10 and 20 mg of 25% Zn-PCL showed similar inhibition, which was weaker 495 
compared to 30 and 40 mg of the dressing.  In addition, there was a time delay of the growth (34 – 496 
82 min). These results suggest that increasing the concentration of Zn to 25% (w/w) increases the 497 
inhibition, however, it is not as effective as Ag or Cu. This is most likely due to a weaker bactericidal 498 
efficacy and lower release rate of Zn compared to Ag and Cu.  Consequently, higher amounts of Zn 499 
may be required to be incorporated into the dressing to compensate for the low release rate and 500 
efficacy to achieve similar inhibition of Cu or Ag. This may present certain difficulties during 501 
formulation and an increase in cost. However, this may not be required as Zn can be incorporated 502 
into the dressing to benefit from its healing properties (especially in patients with zinc deficiency), in 503 
addition to the weaker antimicrobial efficacy.  504 
It is important to make some clarifications regarding the nature of the assay method (IMC) used in 505 
this work. Any in vitro method will differ from the in vivo event, and the relevancy of these 506 
differences will depend on how the data is used. In this case, the in vivo environment is extremely 507 
difficult to reproduce. In a wound environment, bacteria can grow as biofilms or micro-colonies 508 
rather than planktonic cultures which can influence the susceptibility of the microorganism to an 509 
antibacterial agent (James et al., 2008). For instance, it has been suggested that the bactericidal 510 
concentration of silver required to eradicate biofilms of Pseudomonas aeruginosa is 10 to 100 fold 511 
higher than what is required to eradicate planktonic bacteria (Bjarnsholt et al., 2007). This would 512 
suggest that the concentrations used in this work might need to be increased to eradicate biofilms, 513 
since in the experiments reported here, the organism is growing in planktonic culture. In addition, 514 
the antimicrobial effect of metal ions is known to be strain dependent (Ruparelia et al., 2008). It is 515 
important to note that the metal release would be lower in skin versus suspending solution, 516 
although the release could be promoted increasing the metal loading in the filaments, so in the 3D 517 
printed wound dressings as shown in the ICP data. It is already reported that increasing the drug 518 
loading in 3D printed formulations increased drug release since there is less matrix compound (in 519 
this case PCL) avoiding the release of the active compounds (Goyanes et al., 2016b). The main aim of 520 
the microbiology experiments was to evaluate the efficacy of the metal loaded PCL wound dressings 521 
against a known skin pathogen (S. aureus), and to gain insights on how 3D printing might influence 522 
the outcome.  523 
Since optimal moisture content maintains the vitality of tissue and promotes wound healing, 524 
theoretically, it would be possible to modify the thickness of the wounds dressings or to create 525 
regions with small gaps between the layers to modify the vapour permeability. 526 
 527 
4 Conclusion 528 
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The results clearly demonstrate the utility of hot melt extrusion as a novel method to incorporate 529 
antimicrobial Ag, Cu and Zn into polycaprolactone filaments that allow the 3D printing of 530 
personalised wound dressings. 3D printed dressings demonstrated a clear advantage over 531 
conventional flat dressings as they are anatomically adaptable. This method takes advantage of 3D 532 
scanning to create 3D models of body parts which are then 3D printed in a personalised therapy. Ag-533 
PCL and Cu-PCL dressings showed the most bactericidal properties against S. aureus which is a 534 
common bacterium to causes skin infections. This study therefore demonstrates a simple method to 535 
produce customizable wound dressings that can be tailored to individual patients in regards to 536 
shape, size and antimicrobial agents.  537 
 538 
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Figure Captions 639 
Figure 1. Filaments loaded with metals produced, from left to right: plain PCL, Ag (10% w/w)-PCL, Zn 640 
(10% w/w)-PCL, Zn (25% w/w)-PCL, Cu (10% w/w)-PCL and Cu (25% w/w)-PCL. 641 
Figure 2. SEM images of: (A) plain PCL, (B) Ag (10% w/w)-PCL, (C) Cu (10% w/w)-PCL, (D) Cu (25% 642 
w/w)-PCL, (E) Zn (10% w/w)-PCL and (F) Zn (25% w/w)-PCL. 643 
Figure 3. 3D scan model of a nose (left) and the printed wound dressing of this model with Cu-PCL 644 
(right). 645 
Figure 4. FTIR spectra of the 3D printed dressings. 646 
Figure 5. DSC analysis of indicated PCL wound dressings. Exothermic up.  647 
Figure 6. Dissolution profiles of Ag (10% w/w)-PCL, Cu (10% w/w)-PCL, Cu (25% w/w)-PCL, Zn (10% 648 
w/w)-PCL and Zn (25% w/w)-PCL in phosphate buffer (pH 7.4).  649 
Figure 7. Growth of S. aureus by showing the power generated of bacterial cells vs. time in the 650 
presence of increasing amount of dressing containing: (A) control experiments with no PCL or any 651 
metal ions, (B) plain PCL, (C) Ag (10% w/w)-PCL, (D) Cu (10% w/w)-PCL, (E) Cu (25% w/w)-PCL, (F) 652 
control experiment of plain CuSO4 powder in broth and water without any PCL or bacteria, (G) Zn 653 
(10% w/w)-PCL and (H) Zn (25% w/w)-PCL. All experiments were performed at 37 °C over 48 h. 654 
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Appendix 1 682 
  683 
 684 
Figure 8. 3D scan model of an ear (left) and the printed wound dressing of this model with Ag-PCL (right). 685 
